4D dynamic LAFOV FDG-PET to tell leftover cancer from post-radiation inflammation in head and neck squamous cell carcinoma
Official title: Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiation Inflammation in Head Neck SCC Treated by Radiotherapy.
Run by University Hospital, Brest · NCT07417605 · Data updated 2026-11-12
This study will test whether a 4D dynamic long‑axial‑field‑of‑view FDG‑PET scan can tell remaining head and neck squamous cell cancer from normal post‑radiation inflammation in adults about three months after finishing curative radiotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | University Hospital, Brest Academic / other |
| Drugs / interventions | radiation |
| Locations | 3 sites (Brest and 2 other locations) |
| Status | Recruiting |
| Started | April 13, 2026 |
| Main results expected | June 13, 2029 |
| Study ends | June 13, 2029 |
| Registry record updated | July 13, 2026 |
| Trial ID | NCT07417605 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with confirmed head and neck squamous cell carcinoma who completed curative external radiotherapy and are scheduled for a three‑month therapeutic FDG‑PET evaluation and can consent to the scan are ideal candidates.
✕Probably not a fit
Patients who are pregnant or breastfeeding, have hypersensitivity to 18F‑FDG, have non‑squamous histology, did not complete the curative radiotherapy regimen, or refuse participation are not expected to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter observational imaging study enrolling adults with head and neck squamous cell carcinoma who completed curative external radiotherapy. Participants undergo a 4D dynamic long‑axial‑field‑of‑view FDG‑PET acquisition at the routine three‑month post‑treatment therapeutic assessment. Dynamic PET data will be analyzed to distinguish residual viable tumor from post‑radiation inflammatory changes using kinetic/temporal imaging parameters. Imaging results will be compared with clinical follow‑up and, when available, biopsy or additional imaging to determine diagnostic performance.
Why it matters
Potential benefit: If successful, the approach could reduce unnecessary biopsies and delays by improving accuracy in telling residual tumor from post‑radiation inflammation.
How similar studies have gone: Prior smaller studies of dynamic FDG‑PET have shown promise in separating inflammation from tumor, but the use of 4D long‑axial‑field‑of‑view PET for this purpose is relatively new and less well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient ≥ 18 years of age * Presenting with head and neck squamous cell carcinoma * Completed curative treatment with external radiation therapy * Eligible for dynamic LAFOV FDG-PET scan for therapeutic evaluation at 3 months * Having given consent for the end-of-treatment consultation Exclusion Criteria: * Hypersensitivity to 18F-FDG or other excipients contained in the contrast agent * Pregnancy or breastfeeding * History of treated upper gastrointestinal tract cancer * Other histology * Incomplete RTE treatment regimen * Refusal to participate
Where it's running
-
CHU Brest
Brest, France Recruiting -
Centre finistérien de radiothérapie et d'oncologie - site Clinique Pasteur
Brest, France Not yet recruiting -
Centre finistérien de radiothérapie et d'oncologie - Site de l'hôpital La Cavale Blanche
Brest, France Not yet recruiting
Study contacts
- Study coordinator: Ronan ABGRAL, Pr
- Email: ronan.abgral@chu-brest.fr
- Phone: +332 98 22 30 69
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors
This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.
-
Adaptive daily replanning of radiotherapy for head and neck cancer.
This tests whether doing same-day replanning of radiotherapy each treatment can reduce side effects for people receiving curative radiotherapy for head and neck squamous cell carcinoma.
-
Postbiotix-HLA™ with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma.
This trial will test whether taking the postbiotic supplement Postbiotix-HLA™ with first-line pembrolizumab reduces immune-related side effects and alters microbiota in people with recurrent or metastatic head and neck squamous cell carcinoma.
-
Early PET/CT response after first‑line pembrolizumab in recurrent or metastatic head and neck cancer
This project will see if an 18F‑FDG PET/CT scan after two doses of pembrolizumab can tell who is responding among patients with recurrent or metastatic PD‑L1 CPS ≥1 head and neck cancer.
-
Postoperative radiotherapy with nimotuzumab followed by bemcentinib for high-risk head and neck cancer patients who can't take cisplatin
This study will see if adding nimotuzumab during postoperative radiotherapy followed by bemcentinib can help prevent recurrence in high-risk head and neck cancer patients who are unable to receive cisplatin.
-
Radiotherapy with nimotuzumab versus radiotherapy alone for platinum-ineligible advanced head and neck squamous cell carcinoma
This trial tests whether adding nimotuzumab to radiotherapy helps people with advanced head and neck squamous cell carcinoma who cannot receive platinum chemotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.